Having trouble accessing articles? Reset your cache.

resTORbio drops respiratory infection program as it looks ahead to Parkinson’s readout

reSTORbio discontinued development of RTB101 to prevent respiratory tract infections after it failed the pivotal PROTECTOR 1 trial, but the company is moving forward with the mTORC1 inhibitor in Parkinson’s disease and other age-related indications.

resTORbio Inc.

Read the full 373 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers